Lexeo Therapeutics
LXEO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +50.9% in FY2025
R. Nolan Townsend is the CEO of Lexeo Therapeutics and was paid $3.7M in FY2025 (Dec), down 17%.
Pay$100 in the stock at the end of FY23 → $74
Executives3
See all- 1R. Nolan TownsendChief Executive Officer and DirectorFY2025
- 2Jenny R. Robertson, J.D.Former Chief Legal OfficerFY2025
- 3Louis TamayoChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allLexeo Therapeutics paid its 3 named executives $7.5M in total in FY2025 (Dec). CEO R. Nolan Townsend was paid $3.7M of that.
| Name | |||
|---|---|---|---|
| R. Nolan TownsendChief Executive Officer and Director | |||
| Jenny R. Robertson, J.D.Former Chief Legal Officer | |||
| Louis TamayoChief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Lexeo Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board7
See all- Steven Altschuler, M.D.Chair · 4 yr on the boardIndependentCompensation, Science and Technology—Paid as an executive
- Mette Kirstine AggerDirector · 5 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
- R. Nolan TownsendDirector · 5 yr on the boardNot independent—Paid as an executive
- Paula HJ CholmondeleyDirector · 4 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Brenda Cooperstone, M.D.Director · 2 yr on the boardIndependentNominating and Corporate Governance, Science and Technology (Chair)—Paid as an executive
- Laura Sepp-Lorenzino, Ph.D.Director · -1 yr on the boardIndependentScience and Technology—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 30, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 24, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 11, 2024 | FY2023 |
